Close
Practical Applications of New Agents in Oncology
Saturday, February 17, 2024
to
Sunday, February 18, 2024
Register today
-
About
About This Event
Join us for the 26th annual Practical Applications of New Agents in Oncology (PANAO), a nationally recognized conference for health care professionals interested in learning about new anticancer agents and treatments. The nationally recognized speakers presenting at this conference will discuss the advances in agents and the therapeutic paradigms that overlap in different disease specialties.
Hematology and medical oncology physicians, researchers, fellows, residents, nurse practitioners, physician assistants, registered nurses, pharmacists, and clinical research coordinators are invited to attend.
Topics will include:
- Drug development in epigenetic regulation
- Gene therapy
- Novel Drug Development in Oncology
It is a continuing education (CME) activity designed for healthcare professionals specializing in oncology and hematology. The University of Texas Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas Health Science Center San Antonio designates this live activity AMA PRA Category 1 Credits™.
See the photos from the PANAO 2023 symposium!
-
Agenda
Agenda
Saturday, February 17, 2024 Time Session 7:15-8:00 a.m. Registration and breakfast 8:00-8:05 a.m. Opening remarks 8:05-10:25 a.m. Session 1: New drugs in oncology Moderator:
John Sarantopoulos, MD
Mays Cancer Center at UT Health San Antonio8:05-8:45 a.m. Overview of novel drug development in oncology
Andrew Brenner, MD
Mays Cancer Center at UT Health San Antonio8:45-9:15 a.m. Breast cancer Heather McArthur, MD
UT Southwestern Medical Center9:15-9:45 a.m. Drug development in KRAS inhibitors and pancreatic cancer Shubham Pant, MD
MD Anderson Cancer Center9:45-10:15 a.m. Advances in NSCLC:
Non-TKI targets and focus on KRAS, MTAP and BET bromodomain inhibitorsJia Luo, MD
Dana Faber Cancer Institute10:15-10:25 a.m. Q&A session 10:25-10:40 a.m. Break and exhibition 10:40 a.m.-12:20 p.m. Session 2: New drugs in oncology Moderator:
Devi Meyyappan, MD
Mays Cancer Center at UT Health San Antonio10:40-11:10 a.m. Novel therapies in thoracic malignancies, including ADC, bi-specifics and CAR-T Bingnan Zhang, MD
MD Anderson Cancer Center11:10-11:40 a.m. Drug development in colorectal cancers Anna Capasso, MD, PhD
University of Texas at Austin11:40 a.m. – 12:10 p.m. Drug development in GU cancers Chethan Ramamurthy, MD
Merck12:10-12:20 p.m. Q&A session 12:20-1:20 p.m. Lunch, networking and exhibition 1:20-4:25 p.m. Session 3: New drugs in hematology Moderator:
Matthew Butler, MD
Mays Cancer Center at UT Health San Antonio1:20-2:00 p.m. Overview of new drugs in classical hematology Usha Perepu, MD
Mays Cancer Center at UT Health San Antonio2:00-2:30 p.m. New drugs and gene therapy in hemophilia Deanna Maida, MD
Mays Cancer Center at UT Health San Antonio2:30-3:00 p.m. Advances and future direction of CAR T-cell therapy Sattva Neelapu, MD
MD Anderson Cancer Center3:00-3:10 p.m. Break and exhibition 3:10-3:40 p.m. Advances in acute myeloid leukemia Kevin Kelly, MD
University of South California3:40-4:10 p.m. Advances in new drugs in lymphoma Leon Bernal-Mizrachi, MD
Emory University4:10-4:25 p.m. Q&A session Sunday, February 18, 2024 Time Session 7:15-8:15 a.m. Registration and breakfast 8:15-10:40 a.m. Session 4: Drug development and translational research Moderator:
Daruka Mahadevan, MD, PhD
Mays Cancer Center at UT Health San Antonio8:15-8:45 a.m. Drug and research development in HR repair Patrick Sung, PhD
Mays Cancer Center at UT Health San Antonio8:45-9:15 a.m. Non-homologous end joining (NHEJ) DNA repair targeted therapies in development Daruka Mahadevan, MD, PhD
Mays Cancer Center at UT Health San Antonio9:15-9:25 a.m. Break and exhibits 9:25-9:55 a.m. Investigator initiated trial (lung cancer) Josephine Taverna, MD
Mays Cancer Center at UT Health San Antonio9:55-10:25 a.m. Translational research (Investigator initiated trials) Daohong Zhou, MD
Mays Cancer Center at UT Health San Antonio10:25-10:40 a.m. Target chemotherapy-induced polyploidy, a known mechanism of therapeutic resistance Patrick Conway, PhD candidate
Mays Cancer Center at UT Health San Antonio10:40-10:55 a.m. Q&A session 10:55 a.m. – 12:05 p.m. Session 5: Case Studies in Molecular Targeted Treatment of Cancer Moderators:
Jeanne Kowalski, PhD
UT Dell Medical School
Devi Meyyappen, MD
Mays Cancer Center at UT Health San Antonio10:55-11:25 a.m. My cancer molecular information exchange:
Building a patient-centric molecular treatment data fabric for clinical decision supportJeanne Kowalski, PhD
UT Dell Medical School11:25-11:55 a.m. Bioinformatics in cancer treatment session 11:25-11:40 a.m. Bioinformatics in cancer treatment
Case 1: HER2-negative stomach adenocarcinomaAnna Capasso, MD
University of Texas at Austin11:40-11:55 a.m. Bioinformatics in cancer treatment
Case 2: mEFGR SCLCTamarah Aldawoodi, MD
Mays Cancer Center at UT Health San Antonio11:55-12:05 p.m. Q&A session 12:05-1:10 p.m. Lunch, networking and exhibition 1:10-2:15 p.m. Session 6: Clinical trials Moderator:
John Sarantopoulos, MD
Mays Cancer Center at UT Health San Antonio1:10-1:30 p.m. Pharmacy: Role of pharmacists in phase 1 trial Jenny Tran, PharmD
University Health System1:30-1:50 p.m. Patient navigation in clinical trials Leslie Villarreal, RN
Mays Cancer Center at UT Health San Antonio1:50-2:10 p.m. Q&A session 2:10 p.m. – 2:15 p.m. Closing remarks -
Date and Time
Date and Time
- Saturday, February 17, 2024, 7:00AM
- to Sunday, February 18, 2024, 6:00PM
-
Location
Location
-
Contact
Contact
For questions or inquiries about this event, please contact Brittany Taylor.
For questions or inquiries about exhibiting, please contact Hugo Flores.
-
Exhibitor Details
Exhibitor Details
All-day beverages, breakfast and lunch will be placed in the same room as the exhibits. Exhibit hours will be Saturday, Feb. 17, 7:00 a.m. – 5:30 p.m. and Sunday, Feb. 18, from 7:00 a.m. – 4:30 p.m. Exhibitors are welcome to display until 5:00 p.m. on Sunday. Gamification will be used to encourage interaction between the exhibitors and attendees.
Exhibitors will receive a 6-foot by 3-foot table, which gives full access to the meeting and two exhibit staff, a value of $900, or sponsorship in any amount, that will help defray the reasonable costs associated with non-educational expenses.
Submit your exhibit and support request by February 1, 2024.